Clinical trialCLINICALTRIALSToday
Researchers are testing a new drug called Sutetinib Maleate Capsule to treat advanced lung cancer in patients who have specific uncommon mutations in their cancer cells. This is a Phase 2 study, which means the drug has already been tested for safety in a small group and now researchers want to see how well it works in a larger group of about 99 patients. The study is currently accepting new participants at multiple hospitals.
WHY IT MATTERSThis trial offers access to a targeted therapy specifically designed for patients with non-small cell lung cancer carrying rare EGFR mutations (L861Q, G719X, S768I) who may have limited treatment options.
Clinical trialCLINICALTRIALS3 days ago
Researchers are testing a new cancer drug called sutetinib maleate in people with advanced lung cancer that has specific uncommon genetic mutations. This is a Phase 2 trial, meaning the drug has already been tested in a small group and now researchers want to see if it works better and remains safe in a larger group of 66 patients. The study is currently accepting new participants.
WHY IT MATTERSIf you have metastatic or locally advanced non-small cell lung cancer with uncommon EGFR mutations, this trial offers access to a potentially new treatment option that may not yet be available outside of clinical research.
Clinical trialCLINICALTRIALS3 days ago
Researchers are testing a new drug called BH-30643 for advanced lung cancer patients whose tumors have specific genetic mutations (EGFR or HER2). The study will first figure out the right dose and watch for side effects, then test how well the drug works against the cancer. About 266 patients will participate across multiple hospitals.
WHY IT MATTERSThis trial is now actively recruiting patients with EGFR and/or HER2-mutated advanced NSCLC — if you have this genetic profile and have exhausted standard treatments, you may be eligible to access a potentially new treatment option.